Prostate Cancer

Dr Morgans discusses how patient access impacts treating metastatic prostate cancer.

Alicia Morgans, MD, MPH, mentions other factors clinicians need to consider before adding PARP inhibitors to metastatic prostate cancer therapy.

Dr Raoul S. Concepcion presents the case of a 69-year-old man with metastatic castration-naïve prostate cancer (mCNPC), and the panel shares their personal approaches to treatment.

Raoul S. Concepcion, MD, FACS, poses polling questions for the audience’s medical specialty and the percent of patients they receive with prostate cancer.

The aim of this meta-analysis is to analyze the efficacy of these drugs in the treatment of mCRPC in terms of progression-free survival (PFS) and overall survival (OS), using the results of completed trials.

Brian T. Helfand, MD, PhD, and Steven E. Finkelstein, MD, discuss the potential of 18F-fluciclovine PET/CT to guide prostate cancer decision-making.

PSA testing rates for prostate cancer increased among men after the US Preventive Services Task Force released updated guidance in 2017 that reversed the recommendations from previous guidance in 2012.

An expert explains PARP inhibitor use in the metastatic prostate cancer treatment landscape and typical adverse events seen during therapies.

Alicia Morgans, MD, MPH, discusses how to select the best treatment for patients with metastatic prostate cancer and the importance of monitoring them while on therapy.

Investigators noted evident racial and ethnic disparities among patients with high prostate-specific antigen levels who received subsequent prostate MRI imaging.

The utilization of 68Ga-PSMA-11 PET allowed for positive sensitivity and specificity scores for patients with intermediate to high-risk prostate cancer following radical prostatectomy and lymph node dissection.

The recent episode of the "Oncology Peer Review On-The-Go" podcast features Alexandra Sokolova, MD, discussing her article on germline testing and NCCN guidelines for patients with prostate cancer.

Dr Morgans examines systemic treatment options for patients with metastatic castration-resistant prostate cancer.

An expert considers the role of BRCA1/2 mutations in metastatic prostate cancer.

Research from an observational study suggests it will take time for sexual satisfaction scores to improve among patients with erectile dysfunction due to robot-assisted radical prostatectomy for localized prostate cancer.

Brian Rini, MD, discussed abstracts presented during the 2021 ESMO Congress that will have an immediate impact on prostate cancer.

Scott Tagawa, MD, spoke about the implications of the results from his research on treatment patterns of patients with metastatic castration-sensitive prostate cancer, as well as the need for further studies with other data sets.

Dr Morgans discusses biomarker testing protocols and signs to look for during testing.

Alicia Morgans, MD, MPH, explains the different testing that should be done when being diagnosed with metastatic prostate cancer.

Although there was no resulting benefit to overall survival with the addition of short-term androgen deprivation to dose-escalated radiotherapy, patients with intermediate-risk prostate cancer experienced other disease benefits with this treatment approach.

BXCL701 and pembrolizumab may resolve the need for FDA-approved therapies for patients with small cell neuroendocrine prostate cancer, according to investigators.

A specialist describes the advances being made in metastatic prostate cancer and provides some clinical pearls for community oncologists.

Oliver Sartor, MD, discusses the use of rucaparib in treating metastatic prostate cancer.

A key opinion leader explains the role of PARP inhibitors in metastatic prostate cancer and reviews clinical trial data.

Dr. Oliver Sartor illustrates the systemic treatment options for metastatic castration-resistant prostate cancer and what to consider when choosing therapies.

Jun Gong, MD, gives his perspective on a review article published in ONCOLOGY about the necessary relationship between medical oncologists and genetic counselors to help treat patients with prostate cancer.

Results of multiple studies have shown that a proportion of men with advanced prostate cancer carry germline DNA damage repair mutations. This article summarizes recommendations for germline testing in prostate cancer and describes care models for providing counseling and testing.

Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, discussed the phase 2/3 EMPIRE-1 trial focusing on 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy for patients with prostate cancer.

Scott Tagawa, MD, MS, detailed 2 presentations from ESMO’s presidential symposium that he thinks will have an impact on treating patients with metastatic castration-sensitive prostate cancer.

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk survival and progression outcomes from the CARD trial in patients with metastatic castration-resistant prostate cancer.